CytoDyn Inc. (CYDY)
OTCMKTS
· Delayed Price · Currency is USD
0.2000
-0.0040 (-1.96%)
Apr 17, 2025, 4:00 PM EDT
CytoDyn Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
9
Market Cap
251.42M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
SS Innovations International | 20.65M |
Endo Inc. | 1.76B |
Veradigm | 588.02M |
Northwest Biotherapeutics | 1.38M |
Elite Pharmaceuticals | 70.00M |
Glass House Brands | 200.90M |
BioStem Technologies | 210.49M |
American Oncology Network | 1.76B |
CytoDyn News
- 4 weeks ago - March 2025 Letter to Shareholders - GlobeNewsWire
- 7 weeks ago - CytoDyn Announces Promising Survival Observations in mTNBC Patients Treated with Leronlimab - GlobeNewsWire
- 2 months ago - CytoDyn Announces Findings of Statistically Significant Fibrosis Reversal Across Studies with SMC Laboratories - GlobeNewsWire
- 4 months ago - December 2024 Letter to Shareholders - GlobeNewsWire
- 5 months ago - CytoDyn Phase 2 study of leronlimab cleared by FDA - Seeking Alpha
- 5 months ago - CytoDyn Announces FDA Clearance of Its Phase II Oncology Trial - GlobeNewsWire
- 6 months ago - CytoDyn Appoints Dr. Melissa Palmer, M.D., as Lead Consultant in Hepatology; Announces Follow-Up Inflammation Studies with SMC Laboratories - GlobeNewsWire
- 6 months ago - CytoDyn Announces Abstract that Highlights Leronlimab's Potential in Mediating ART-Free Viral Control in Infant Rhesus Macaques - GlobeNewsWire